Your browser is unsupported

We recommend using the latest version of IE11, Edge, Chrome, Firefox or Safari.

In this section

2012

Nov-Dec 2012 edition

  • New Data for Dabigatran: A Focus on Efficacy and Safety      
  • Mortality Risk with Digoxin???   

Sep-Oct 2012 edition

  • Management of Pulmonary Arterial Hypertension in Children      
  • Guideline Update for Gonorrhea Treatment   

Jul-Aug 2012 edition

  • Protecting Pediatric Patients from Pertussis—Updated Recommendations
  • New safety communications from the FDA - ondansetron and cefepime
  • Clinical Care Guideline: Antimicrobial Prophylaxis for Surgery

May-Jun 2012 edition

  • Adverse drug events and the risk of hospitalization among elderly patients
  • Anticoagulant reversal-dabigatran and rivaroxaban
  • Guideline update: IDSA guidelines on diabetic foot infections
  • P&T Committee Formulary Action

Mar-Apr 2012 edition

  • Food and Drug Administration Safety Update
  • Recent Findings of Cardiovascular Risk Associated with Medication Use
  • P&T Committee Formulary Action

Jan-Feb 2012 edition

  • ACCP Antithrombosis Guidelines Updated
  • Drug Allergy vs. Pseudo-allergey: What’s the Difference?
  • P&T Formulary Review: Deciphering the Process
  • Medication Prescribing: are you Conservative or Liberal?
Top